Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1220 results
February 2016
-
Media Release
Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.
Acquisition to add minimally-invasive glaucoma surgery (MIGS) device to pipeline, expanding Alcon's surgical presence in a new category to treat glaucoma The goal of MIGS is to reduce or… -
Media Release
Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEA
Sandoz acquires rights to PF-06438179 (biosimilar infliximab) in the European Economic Area (EEA)* Sandoz plans to complete Phase III development program and file for registration in the EU… -
Media Release
Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
Sandoz' late-stage biosimilar pipeline gains momentum with sustained investment - five of 10 planned regulatory filings achieved Sandoz believes that the totality of evidence in its submission,…
January 2016
-
Media Release
Novartis Foundation commemorates World Leprosy Day with its continued efforts to go the last mile toward elimination
2016 marks 30 years of commitment by the Novartis Foundation to support people affected by leprosy and to end this ancient disease New strategy from the Novartis Foundation to accelerate… -
Media Release
Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations
Strong growth (cc) in full year sales, core operating income and core EPS[2] Net sales up 5% (cc) and core operating income up 10% (cc) Core operating income margin up 1.3 percentage points (… -
Media Release
Novartis a enregistré, en 2015, une forte croissance des ventes et une hausse de sa marge core (tcc1) et annonce des plans pour accélérer la croissance d'Alcon et rationaliser les opérations du Groupe
Forte croissance (tcc) des ventes, du résultat opérationnel core et du BPA core[2] en 2015 Chiffre d'affaires net en hausse de 5% (tcc) et résultat opérationnel core en augmentation de 10% (tcc… -
Media Release
Novartis erzielt 2015 eine kräftige Steigerung des Umsatzes und der Kern-gewinnmarge (kWk[1]); Pläne zur Wachstumsbeschleunigung bei Alcon und zur Straffung der Konzernaktivitäten bekannt gegeben
Solides Wachstum (kWk) beim Umsatz, operativen Kernergebnis und Kerngewinn pro Aktie[2] im Gesamtjahr Der Nettoumsatz steigt um 5% (kWk), das operative Kernergebnis wächst um 10% (kWk) Die… -
Media Release
Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US
Cosentyx is the first and only interleukin-17A (IL-17A) inhibitor approved for adult patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) FDA approval for Cosentyx is… -
Media Release
Novartis continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface Oncology
Agreement gives Novartis access to four pre-clinical programs that target regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumor microenvironment… -
Media Release
Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPD
The Breezhaler(TM) inhaler is the device for Novartis' portfolio of COPD treatments of Onbrez and Seebri, and Ultibro, the leading LABA/LAMA treatment The collaboration further supports Novartis'…
December 2015
-
Media Release
Novartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patients
Cosentyx (secukinumab) is the first IL-17A inhibitor approved in Europe to treat ankylosing spondylitis (AS) and first treatment advance in 16 years since anti-tumor necrosis factor (anti-TNF)… -
Media Release
300 million child-friendly antimalarial treatments supplied without profit by Novartis
Coartem® Dispersible*, the first WHO prequalified[1] pediatric antimalarial treatment, has become the standard of care in over 30 malaria-endemic countries Since 2009, Novartis has supplied 300…